These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1544 related items for PubMed ID: 9251066

  • 1. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [Abstract] [Full Text] [Related]

  • 2. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
    Illi A, Sundberg S, Ojala-Karlsson P, Scheinin M, Gordin A.
    Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
    [Abstract] [Full Text] [Related]

  • 3. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
    Ferreira JJ, Almeida L, Cunha L, Ticmeanu M, Rosa MM, Januário C, Mitu CE, Coelho M, Correia-Guedes L, Morgadinho A, Nunes T, Wright LC, Falcão A, Sampaio C, Soares-da-Silva P.
    Clin Neuropharmacol; 2008 Apr; 31(1):2-18. PubMed ID: 18303486
    [Abstract] [Full Text] [Related]

  • 4. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
    Heikkinen H, Nutt JG, LeWitt PA, Koller WC, Gordin A.
    Clin Neuropharmacol; 2001 Apr; 24(3):150-7. PubMed ID: 11391126
    [Abstract] [Full Text] [Related]

  • 5. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
    Ruottinen HM, Rinne JO, Oikonen VJ, Bergman JR, Haaparanta MT, Solin OH, Ruotsalainen UH, Rinne UK.
    Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
    [Abstract] [Full Text] [Related]

  • 6. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
    Ishihara A, Miyachi T, Nakamura T, Ohtsuki T, Kimura Y, Kihira K, Yamawaki T, Matsumoto M.
    Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701
    [Abstract] [Full Text] [Related]

  • 7. Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
    Hamaue N, Ogata A, Terado M, Tsuchida S, Yabe I, Sasaki H, Hirafuji M, Togashi H, Aoki T.
    Brain Res; 2010 Jan 14; 1309():110-5. PubMed ID: 19879254
    [Abstract] [Full Text] [Related]

  • 8. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J, US01 Study Team.
    Arch Neurol; 2004 Oct 14; 61(10):1563-8. PubMed ID: 15477510
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T, Machado R, Rocha JF, Fernandes-Lopes C, Costa R, Torrão L, Loureiro AI, Falcão A, Vaz-da-Silva M, Wright L, Almeida L, Soares-da-Silva P.
    Clin Ther; 2009 Oct 14; 31(10):2258-71. PubMed ID: 19922897
    [Abstract] [Full Text] [Related]

  • 10. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
    Corvol JC, Bonnet C, Charbonnier-Beaupel F, Bonnet AM, Fiévet MH, Bellanger A, Roze E, Meliksetyan G, Ben Djebara M, Hartmann A, Lacomblez L, Vrignaud C, Zahr N, Agid Y, Costentin J, Hulot JS, Vidailhet M.
    Ann Neurol; 2011 Jan 14; 69(1):111-8. PubMed ID: 21280081
    [Abstract] [Full Text] [Related]

  • 11. Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone.
    Trocóniz IF, Naukkarinen TH, Ruottinen HM, Rinne UK, Gordin A, Karlsson MO.
    Clin Pharmacol Ther; 1998 Jul 14; 64(1):106-16. PubMed ID: 9695725
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U, Kaldonska M, Klodowska-Duda G, Wyska E, Safranow K, Bialecka M, Gawronska-Szklarz B.
    Clin Neuropharmacol; 2010 May 14; 33(3):135-41. PubMed ID: 20216409
    [Abstract] [Full Text] [Related]

  • 13. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
    Zijlmans JC, Debilly B, Rascol O, Lees AJ, Durif F.
    Mov Disord; 2004 Sep 14; 19(9):1006-1011. PubMed ID: 15372589
    [Abstract] [Full Text] [Related]

  • 14. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.
    Hauser RA, Molho E, Shale H, Pedder S, Dorflinger EE.
    Mov Disord; 1998 Jul 14; 13(4):643-7. PubMed ID: 9686768
    [Abstract] [Full Text] [Related]

  • 15. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
    Heikkinen H, Varhe A, Laine T, Puttonen J, Kela M, Kaakkola S, Reinikainen K.
    Br J Clin Pharmacol; 2002 Oct 14; 54(4):363-71. PubMed ID: 12392583
    [Abstract] [Full Text] [Related]

  • 16. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ, Swope DM, Dashtipour K.
    Clin Ther; 2007 Sep 14; 29(9):1825-49. PubMed ID: 18035186
    [Abstract] [Full Text] [Related]

  • 17. The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J, Sovijärvi A, Kaakkola S, Gordin A, Teräväinen H.
    Clin Neuropharmacol; 2001 Sep 14; 24(1):50-7. PubMed ID: 11290882
    [Abstract] [Full Text] [Related]

  • 18. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E, LARGO study group.
    Lancet; 2001 Sep 14; 365(9463):947-54. PubMed ID: 15766996
    [Abstract] [Full Text] [Related]

  • 19. [Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease].
    Kulisevsky J.
    Neurologia; 1999 Sep 14; 14(7):349-58. PubMed ID: 10570622
    [Abstract] [Full Text] [Related]

  • 20. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW.
    Ann Neurol; 2010 Jul 14; 68(1):18-27. PubMed ID: 20582993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 78.